 The antibody-drug conjugate trastuzumab deruxtecan may be an effective treatment for patients with HER2-positive cancers whose disease has progressed despite the use of other therapies. In a phase I trial, patients treated with the drug had high overall response rates and rates of tumor shrinkage, but many also experienced serious gastrointestinal and hematologic side effects.